Latent Tuberculosis
55
10
13
28
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.6%
2 terminated out of 55 trials
93.3%
+6.8% vs benchmark
16%
9 trials in Phase 3/4
21%
6 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (55)
Training Protocol on the Natural History of Tuberculosis
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
Brief Educational Video for Patients Prescribed LTBI Treatment
TB Screening Improves Preventive Therapy Uptake
Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda
Tuberculosis Clinical Trials Consortium Study 35
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
Economic Incentives and vDOT for Latent Tuberculosis Infection
Evaluating the Accuracy of New Tests for TB Infection Diagnosis
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Improving Rhode Island's Tuberculosis Preventive Services in Primary Care
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Screening for Tuberculosis in Pregnancy
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease